DeveloGen
HOME COMPANY PRODUCTS SERVICES NEWS AND PRESS CAREER
 You are here    Home / Company / History /
 
Company
About us
History
Team
 
History

2010 Evotec AG to Acquire Majority Holding in DeveloGen AG

2010 DeveloGen AG receives US$ 500.000 Funding from the Juvenile Diabetes Research Foundation for Beta Cell Research

2009 Boehringer Ingelheim and DeveloGen AG announce agreement in the field of diabetes, obesity and the metabolic syndrome

2008 DeveloGen completes phase I clinical trial for DG3173

2007 DeveloGen and Teva enter into exclusive license agreement for PKB technology for the treatment of cancer

2007 DeveloGen and Andromeda completed final agreement for DiaPep277® program

2006 DeveloGen receives grant for DiaPep277® program

2006 DiaPep277® mechanism of action demonstrated

2006 DeveloGen and its CEO, Dr. Guenther Karmann, part by mutual agreement; Dr. Cord Dohrmann, CSO, appointed to the Management Board

2006 DeveloGen receives JDRF Grant for Beta-Cell Regeneration Program

2006 DeveloGen announces changes to Scientific Advisory Board

2005 DeveloGen announces End-of-Phase II Meeting with FDA, EMEA Scientific Advice Meeting and First-Patient-In for phase III clinical trial of DiaPep277®

2005 DeveloGen presents positive phase II data at EASD Conference

2004 Debiopharm and DeveloGen announce partnering of Myasthenia Gravis Program

2004 DeveloGen AG receives approval for funding from the BioChancePLUS Programme of the Federal Ministry of Education and Research (BMBF) for developing a project in the field of diabetic complications

2004 Shareholders of DeveloGen and Peptor approve Merger Plan. DeveloGen closes 3rd Financing Round

2004 Completed the last two phase II clinical studies in type 1 diabetes. Meta-analysis of clinical data from all studies showed DiaPep277® has an effect on arresting type 1 diabetes progression as well as improving metabolic control.

2003 DeveloGen and Peptor enter into Agreement and Plan of Merger
2003 DeveloGen AG and the Max Planck Institute for biophysical chemistry were awarded the prize for cooperation by the government of the state of Lower Saxony.
2002 Dr. Guenther Karmann was appointed as Chief Executive Officer. Dr. Herbert Stadler stepped down as CEO to join the Supervisory Board. Dr. Klaus Brandau was appointed as Chairman of the Supervisory Board.
2001 DeveloGen completed a Euro 40 million private financing round led by Dresdner Kleinwort Capital and Techno Venture Management.
2000 DeveloGen merges with HepaVec AG, a gene delivery and liver disease biotechnology company.
1999 DeveloGen and its founders Prof. Dr. Peter Gruss and Prof. Dr. Herbert Jaeckle are awarded the German President's prize for innovation.

1999 The first round of financing is completed, raising DM 5.5 million from Atlas Venture, Global Life Science and IMH.

  
1998 DeveloGen started operations with Dr. Herbert Stadler as Chief Executive Officer.
1997 DeveloGen was founded by the renowned authorities in developmental biology Prof. Dr. Peter Gruss and Prof. Dr. Herbert Jaeckle of the Max Planck Institute and Prof. Dr. Wolfgang Driever of The University of Freiburg, Germany, and the experienced entrepreneur Dr. Herbert Stadler.
  SITEMAP      IMPRINT       CONTACT